NCT06554574View on ClinicalTrials.gov

A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
Healthy
Interventions
DRUG

LTG-305

Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts

Trial Locations (1)

Unknown

Clinical Research Unit, Christchurch

Sponsors
All Listed Sponsors
lead

Latigo Biotherapeutics

INDUSTRY